Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 9, 2018
GAITHERSBURG, Md., May 02, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its first quarter 2018 financial and operating results following the close of U.S. financial markets on Wednesday, May 9, 2018.
Conference call details are as follows:
| Date: | May 9, 2018 | |
| Time: | 4:30 p.m. U.S. Eastern Time (ET) | |
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) | |
| Passcode: | 3687883 | |
| Webcast: | www.novavax.com, “Investors”/ “Events” |
Conference call and webcast replay:
| Dates: | Starting at 7:30 p.m. ET, May 9, 2018 until | |
| 7:30 p.m. ET May 16, 2018 | ||
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) | |
| Passcode: | 3687883 | |
| Webcast: | www.novavax.com, “Investors”/ “Events”, until August 9, 2017 |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases. Its RSV and influenza nanoparticle vaccine candidates are Novavax’ most advanced clinical programs and are at the forefront of Novavax’ efforts to improve global health. For more information, please visit www.novavax.com.
Contact:
Investors
Erika Trahan
Senior Manager, Investor & Public Relations
ir@novavax.com
240-268-2000
Westwicke Partners
John Woolford
john.woolford@westwicke.com
443-213-0506
Media
Sam Brown
Mike Beyer
mikebeyer@sambrown.com
312-961-2502
Latest Health & Supplement Reviews
- YuSleep Reviews (EXPOSED) Doctor Explains Deep Sleep Benefits, Hidden Risks & Real Consumers Results In 2026
- Neuro Energizer Reviews and Complaints 2026: How This Neuro-Sonic Breakthrough Is Reshaping Cognitive Therapy, Memory & Daily Focus
- Gluco6 Reviews and Complaints (March 2026) Real User Data on Natural Blood Sugar Balance and Glucose Stability